X4 Pharmaceuticals Inc
XFOR
Company Profile
Business description
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Contact
61 North Beacon Street
4th Floor
BostonMA02134
USAT: +1 857 529-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.20 | 79.30 | 0.91% |
| CAC 40 | 7,817.16 | 53.32 | 0.69% |
| DAX 40 | 24,244.66 | 153.04 | 0.64% |
| Dow JONES (US) | 42,591.65 | 72.01 | 0.17% |
| FTSE 100 | 8,816.17 | 29.15 | 0.33% |
| HKSE | 23,654.03 | 141.54 | 0.60% |
| NASDAQ | 19,451.74 | 52.78 | 0.27% |
| Nikkei 225 | 37,747.45 | 300.64 | 0.80% |
| NZX 50 Index | 12,494.71 | 167.48 | 1.36% |
| S&P 500 | 5,986.60 | 16.23 | 0.27% |
| S&P/ASX 200 | 8,541.80 | 75.10 | 0.89% |
| SSE Composite Index | 3,376.20 | 14.23 | 0.42% |